S-217622 is the first oral, non-covalent, non-peptidic SARS-CoV-2 3CL (main protease) inhibitor clinical candidate, currently in Ph. II/III trials as a once-daily oral treatment for COVID-19. Unlike paxlovid, the…
Home > S-217622
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.